Mast Cell Activation Syndrome (MCAS) is a hypersensitivity disorder, and subset of
Mast Cell Disease, which has become increasingly recognized over the past three decades.
Since the first case reports were published in the late 1980s,
1
,
2
significant advancements have been made to better understand MCAS characteristics
and determine effective treatment strategies. With improvements in recognition and
modification of diagnostic criteria, it is estimated that up to 17% of the population
has MCAS,
3
,
4
highlighting the importance of clinician education regarding this recently identified
disorder. To better understand the pathophysiology of MCAS—and the pharmacologic interventions
effective in its management—it is important to first begin by discussing the normal
activity of mast cells.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of PeriAnesthesia NursingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Mast cell activation syndrome: proposed diagnostic criteria.J Allergy Clin Immunol. 2010; 126 (e4): 1099-1104
- Carcinoid syndrome and disorders of systemic mast-cell activation including systemic mastocytosis.Endocrinol Metab Clin North Am. 1988; 17: 415-436
- Idiopathic mast cell activation syndrome is more often suspected than diagnosed – a prospective real-life study.Allergy. 2022; 77: 2794-2802
- Diagnosis of mast cell activation syndrome: a global “consensus-2”.Diagnosis (Berl). 2020; 8: 137-152
- Mast cell: a multi-functional master cell.Front Immunol. 2016; 6: 620
- Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.J Hematol Oncol. 2011; 4: 10
- Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper.Allergy. 2015; 70: 755-763
- Mast cell activation syndromes.J Allergy Clin Immunol. 2017; 140: 349-355
The Mast Cell Disease Society, Inc. (TMS). Accessed December 27, 2022. https://tmsforacure.org/
- Vancomycin Flushing Syndrome. StatPearls.StatPearls Publishing, Treasure Island, FL2022
- Kounis syndrome: a new twist on an old disease.Future Cardiol. 2011; 7: 805-824
- Anaphylaxis and anesthesia: controversies and new insights.Anesthesiology. 2009; 111: 1141-1150
- Perioperative anaphylaxis: pathophysiology, clinical presentation and management.BJA Educ. 2019; 19: 313-320
- Anaphylaxis – a practice parameter update 2015.Ann Allergy Asthma Immunol. 2015; 115: 341-384
- Successful treatment of severe adrenaline-resistant anaphylactic shock with glucagon in a patient taking a beta-blocker: a case report.JA Clin Rep. 2021; 7: 86
- Anaphylaxis – a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.J Allergy Clin Immunol. 2020; 145: 1082-1123
- Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management.Clin Chem Lab Med. 2016; 54: 1545-1559
Article info
Publication history
Published online: February 23, 2023
Footnotes
Conflict of Interest: None to report.
Identification
Copyright
© 2023 American Society of PeriAnesthesia Nurses. Published by Elsevier Inc. All rights reserved.
